You just read:

FDA Advisory Committee Recommends Approval of HETLIOZ™ for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind

News provided by

Vanda Pharmaceuticals Inc.

Nov 14, 2013, 10:55 ET